Level Biotechnology Cash Flow Conversion Efficiency
Level Biotechnology cash flow conversion efficiency. Based on the latest financial reports, Level Biotechnology (3118) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$11.81 Million ≈ $372.24K USD) by net assets (NT$562.82 Million ≈ $17.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Level Biotechnology (2017–2024)
Cash flow conversion efficiency of Level Biotechnology from 2017 to 2024. This chart illustrates how Level Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Level Biotechnology for real-time trading data and today's change.
Level Biotechnology Cash Flow Conversion Ratio Explained
Level Biotechnology cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Level Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Level Biotechnology ranked by their cash flow conversion efficiency. Also see Level Biotechnology (3118) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jeil Steel Mfg Co. Ltd
KQ:023440
|
-0.047x |
|
Bicicletas Monark S.A
SA:BMKS3
|
0.016x |
|
Maquia Capital Acquisition Corp
NASDAQ:MAQC
|
0.008x |
|
Redwood Group Ltd
TWO:8426
|
0.179x |
|
Comms Group Ltd
AU:CCG
|
0.068x |
|
MFS Investment Grade Municipal Trust
NYSE:CXH
|
0.023x |
|
BioSmart Co.Ltd
KQ:038460
|
0.042x |
|
Modi Rubber Limited
NSE:MODIRUBBER
|
0.002x |
Annual Cash Flow Conversion Efficiency for Level Biotechnology (2017–2024)
The table below shows the annual cash flow conversion efficiency of Level Biotechnology from 2017 to 2024. Review how much free cash does Level Biotechnology generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$559.91 Million ≈ $17.64 Million |
NT$64.10 Million ≈ $2.02 Million |
0.114x | -10.41% |
| 2023-12-31 | NT$549.47 Million ≈ $17.31 Million |
NT$70.21 Million ≈ $2.21 Million |
0.128x | +6.51% |
| 2022-12-31 | NT$542.40 Million ≈ $17.09 Million |
NT$65.07 Million ≈ $2.05 Million |
0.120x | -58.09% |
| 2021-12-31 | NT$544.84 Million ≈ $17.17 Million |
NT$155.95 Million ≈ $4.91 Million |
0.286x | +82.08% |
| 2020-12-31 | NT$529.43 Million ≈ $16.68 Million |
NT$83.23 Million ≈ $2.62 Million |
0.157x | -25.92% |
| 2019-12-31 | NT$513.75 Million ≈ $16.19 Million |
NT$109.02 Million ≈ $3.43 Million |
0.212x | +295.34% |
| 2018-12-31 | NT$498.78 Million ≈ $15.71 Million |
NT$26.77 Million ≈ $843.50K |
0.054x | -60.68% |
| 2017-12-31 | NT$522.28 Million ≈ $16.45 Million |
NT$71.29 Million ≈ $2.25 Million |
0.136x | -- |
About Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It markets and distributes biomedical precision equipment. The company also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the bio… Read more